Advantages of Celsior solution in graft preservation from non-heart-beating donors in a canine liver transplantation model.
BACKGROUND
The optimal method for preserving livers from non-heart-beating donors (NHBD) is still unknown. We compared the Celsior solution, a new extracellular-type, low-potassium, low-viscosity preservation solution, with the University of Wisconsin (UW) solution in a canine orthotopic liver transplantation from NHBD.


METHODS
Fourteen adult mongrel dogs, weighing 9 to 17 kg, were divided into two groups: the Celsior or the UW group (n = 7 each). The thoracic descending aorta and supradiaphragmatic inferior vena cava were cross-clamped for 20 min to induce warm ischemia as a NHBD model. The liver was flushed with the respective cold preservation solution and then stored at 4 degrees C for 4 h. The grafts were transplanted using the piggy-back technique under portal decompression by leaving the native right lobe as a temporary shunt.


RESULTS
The duration of liver flushing out (min) was shorter (P < 0.05), and the serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, lactate dehydrogenase, lactate, and alpha-glutathione S-transferase concentrations 2 and 6 h after reperfusion of the graft (RPF) were lower (P < 0.05) in the Celsior group than in the UW group. Hepatic tissue blood flow (HTBF) did not deteriorate as much (P < 0.05) in the Celsior group. The serum endothelin-1 level was lower (P < 0.05) in the Celsior group 2 h after RPF. Histopathology of liver specimens revealed portal congestion and hepatocyte necrosis with neutrophil infiltration in the UW group, while these findings were mild in the Celsior group.


CONCLUSIONS
The Celsior solution improves vascular endothelial injury in livers from NHBDs and may have advantages in graft flush and preservation of grafts from NHBDs.
Ohwada
Susumu
S
Second Department of Surgery, Gunma University Faculty of Medicine, 3-39-15 Showa-Machi, Maebashi, 371-8511, Japan. sohwada@med.gunma-u.ac.jp
Sunose
Yutaka
Y
Aiba
Masaaki
M
Tsutsumi
Hirofumi
H
Iwazaki
Shigeru
S
Totsuka
Osamu
O
Matsumoto
Koshi
K
Takeyoshi
Izumi
I
Morishita
Yasuo
Y
D000241:Adenosine / Q000494:pharmacology; D000410:Alanine Transaminase / Q000097:blood; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood / Q000378:metabolism; D004187:Disaccharides / Q000494:pharmacology*; D004285:Dogs; D004573:Electrolytes / Q000494:pharmacology*; D019332:Endothelin-1 / Q000097:blood; D005260:Female; D005971:Glutamates / Q000494:pharmacology*; D005978:Glutathione / Q000494:pharmacology*; D005982:Glutathione Transferase / Q000378:metabolism; D006085:Graft Survival; D006323:Heart Arrest; D006639:Histidine / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D019344:Lactic Acid / Q000378:metabolism; D008099:Liver / Q000201:enzymology / Q000473:pathology / Q000601:surgery; D008102:Liver Circulation / Q000502:physiology; D016031:Liver Transplantation; D008297:Male; D008353:Mannitol / Q000494:pharmacology*; D009504:Neutrophils / Q000473:pathology; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D011887:Raffinose / Q000494:pharmacology
C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D019332:Endothelin-1; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D019344:Lactic Acid; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D007770:L-Lactate Dehydrogenase; D005982:Glutathione Transferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose